Tags

Type your tag names separated by a space and hit enter

Antipsychotic-like effects of cannabidiol and rimonabant: systematic review of animal and human studies.
Curr Pharm Des. 2012; 18(32):5141-55.CP

Abstract

Several lines of experimental and clinical evidence point to a close relationship between cannabis, the endogenous cannabinoid system, and schizophrenia. A variety of animal and human studies found a dysregulation of endocannabinoid signalling in psychosis. Elevated anandamide levels in schizophrenia patients that are negatively correlated with psychotic symptomatology indicate a protective role, whereas 2-arachidonoylglycerol appears to counteract psychosis-related cognitive impairments. Thus, pharmacological manipulation of the endogenous cannabinoid system might be associated with potential antipsychotic properties. In the present systematic review, both preclinical studies using different animal models of psychosis as well as clinical trials investigating the antipsychotic effects of both cannabidiol and rimonabant are presented together with the possible underlying mechanisms of action. The results predominantly confirm the hypothesis of an antipsychotic activity of both cannabinoids. In comparison, cannabidiol appears to be superior to rimonabant with a pharmacological profile similar to atypical antipsychotic drugs.

Authors+Show Affiliations

Department of Psychiatry, LWL University Hospital, Ruhr-University Bochum, Alexandrinenstr. 1-3, 44791 Bochum, Germany. patrik.roser@rub.deNo affiliation info available

Pub Type(s)

Journal Article
Review
Systematic Review

Language

eng

PubMed ID

22716153

Citation

Roser, Patrik, and Ida S. Haussleiter. "Antipsychotic-like Effects of Cannabidiol and Rimonabant: Systematic Review of Animal and Human Studies." Current Pharmaceutical Design, vol. 18, no. 32, 2012, pp. 5141-55.
Roser P, Haussleiter IS. Antipsychotic-like effects of cannabidiol and rimonabant: systematic review of animal and human studies. Curr Pharm Des. 2012;18(32):5141-55.
Roser, P., & Haussleiter, I. S. (2012). Antipsychotic-like effects of cannabidiol and rimonabant: systematic review of animal and human studies. Current Pharmaceutical Design, 18(32), 5141-55.
Roser P, Haussleiter IS. Antipsychotic-like Effects of Cannabidiol and Rimonabant: Systematic Review of Animal and Human Studies. Curr Pharm Des. 2012;18(32):5141-55. PubMed PMID: 22716153.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antipsychotic-like effects of cannabidiol and rimonabant: systematic review of animal and human studies. AU - Roser,Patrik, AU - Haussleiter,Ida S, PY - 2012/03/30/received PY - 2012/04/10/accepted PY - 2012/6/22/entrez PY - 2012/6/22/pubmed PY - 2013/3/26/medline SP - 5141 EP - 55 JF - Current pharmaceutical design JO - Curr Pharm Des VL - 18 IS - 32 N2 - Several lines of experimental and clinical evidence point to a close relationship between cannabis, the endogenous cannabinoid system, and schizophrenia. A variety of animal and human studies found a dysregulation of endocannabinoid signalling in psychosis. Elevated anandamide levels in schizophrenia patients that are negatively correlated with psychotic symptomatology indicate a protective role, whereas 2-arachidonoylglycerol appears to counteract psychosis-related cognitive impairments. Thus, pharmacological manipulation of the endogenous cannabinoid system might be associated with potential antipsychotic properties. In the present systematic review, both preclinical studies using different animal models of psychosis as well as clinical trials investigating the antipsychotic effects of both cannabidiol and rimonabant are presented together with the possible underlying mechanisms of action. The results predominantly confirm the hypothesis of an antipsychotic activity of both cannabinoids. In comparison, cannabidiol appears to be superior to rimonabant with a pharmacological profile similar to atypical antipsychotic drugs. SN - 1873-4286 UR - https://www.unboundmedicine.com/medline/citation/22716153/Antipsychotic_like_effects_of_cannabidiol_and_rimonabant:_systematic_review_of_animal_and_human_studies_ L2 - https://www.ingentaconnect.com/openurl?genre=article&issn=1381-6128&volume=18&issue=32&spage=5141&aulast=Roser DB - PRIME DP - Unbound Medicine ER -